


2024 | Earnings presentation



Disclaimer

This is a brief presentation of the main highlights of the quarterly information of Hospital Mater Dei SA ("Mater Dei" or "Company") for the quarter and semester period ended on June 30, 2024 ("Financial Statements").

This presentation has been summarized and is not intended to be complete. The Company's shareholders and potential investors must always read this presentation together with the Quarterly Information published in the IR and CVM website.

This presentation was prepared for informational purposes only and should not be taken as a request for an offer to buy or sell any securities and should not be treated as an investment recommendation.

No statement, express or otherwise, is made regarding the accuracy, certainty or comprehensiveness of the information contained in this presentation. The Company's past performance is not an indicative of future results. This presentation should not be used as the basis for any agreement or contract.

Information regarding the Mater Dei Hospital, its activities, economic and financial position and the risks inherent to its activities, as well as its financial statements, can be found on the world wide web, on the Mater Dei website (https://ri.materdei.com.br/en).

CEO Comments

Quarter considerations

Porto Dias Divestment

- In May was announced the divestiture of its corporate interest of Hospital Porto Dias holding;
- Portfolio adjustment in a challenging moment for the sector;
- The operation strengthens financial discipline, improvement in receivables, working capital and net indebtedness;
- Completion is subject to fulfillment of certain precedent conditions, already approved by EGM, AMB and CADE.

Drop of ~30% on consolidated receivables

Improvement of 20 days in the average term of receivables

Net Debt / EBITDA of 1,4x with cash inflow of BRL 410 MM



Highlights

Salvador 2 Years anniversary

- 2 years of Salvador opening, offering a broad services variety aiming all the stages of life;
- JCI certification, in December 2023;
- Rewarded physical structure, a collaboration between several professionals that worked towards sustainability that the project require;



New executive board

- Dra. Lara Salvador Geo was elected as the last member of the third Generation in the Company's executive board aligned with the succession process that began last November;
- Lead the Innovation and Patient Experience areas;
- Experience in healthcare companies in Brazil and with a MBA in strategy, change management and healthcare, and fellow in leadership in NYU;

Acquired units' investments

- Premium new emergency room, improvement of protocols and flow, with higher patients from this sector
- Acquisition of strategic lands in Feira de Santana (EMEC)
- Hospital Santa Genoveva new hospitalization beds

UTI Top Performer

- Efficient ICU
- ICU Top Performer
- Cardiology Efficient ICU



Second debentures issue

- BRL 200 million, with interest rate of DI + 0.95% (-65bps from 1st issue);
- AA+(bra) by Fitch for cash position reinforcement;
- Due date for 7 years, Half-yearly interest and amortization for the last 2 years.


Nova Lima opening


- · Opening schedule for August 23;
- With 117 capacity beds;
- Differentiated beds, with integration with external environment;
- Emergency room 24h, complete diagnostic medicine service, medical offices, intensive care units and modern surgical center



Operational highlights


Quarterly avg. operational beds and occupancy rate







% change in number of patients-day versus 2023




Revenue

Average Ticket – BRL Mm / used beds

Net Revenue- R\$ Mm






Costs and expenses



Adjusted EBITDA


EBITDA and EBITDA margin – BRL Mm




Adjusted on 2024 and 6M24 due the impairment of assets by the disinvestment of CSN and by values referring to Nova Lima preoperational

EBITDA reconciliation BRL million	2024	6M24
EBIT	(652.3)	(540.2)
Depreciation and amortization	27.5	54.9
EBITDA	(624.8)	(485.3)
% of net revenue	-106.7%	-41.5%
Impairment of assets	744.1	744.1
Nova Lima preoperational	1.0	1.0
Adjusted EBITDA	120.3	259.9
% of net revenue	20.6%	22.2%


Net income and Cash Flow









Debt and Levarage







A&Q



For questions via audio, please raise your hand to join the line. When announced to ask the question, your microphone will be enabled. We ask for all the questions to be made at once.



If you prefer, write your question directly in the Q&A icon ate the bottom of the screen



Website: ri.materdei.com.br/en E-mail: ri@materdei.com.br

&MaterDei

Rede de Saúde













A3Data...

























